SCHEMBL3925878

SCHEMBL3925878

O=C1CNC2(CCN(S(=O)(=O)c3ccc(Cl)s3)CC2)N1Cc1ccccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
MAPK1 P28482 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 3/20 0.44
GAA P10253 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 5/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
NPSR1 Q6W5P4 1/20 0.39
MCOLN3 Q8TDD5 1/20 0.39
TSHR P16473 2/20 0.38
KMT2A Q03164 1/20 0.38
AKR1B1 P15121 1/20 0.36
HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3925395 0.85 PKM (0.42) LMNASMN1; SMN2TDP1ALDH1A1KDM4E
SCHEMBL3927007 0.82 MEN1 (0.42) LMNASMN1; SMN2ALDH1A1GAAKDM4E
SCHEMBL3917070 0.78 ALDH1A1 (0.38) LMNASMN1; SMN2ALDH1A1GAAKDM4E
SCHEMBL3919448 0.78 PKM (0.50) LMNAALDH1A1HTTCYP2D6CYP2C9
SCHEMBL3917072 0.77 ALDH1A1 (0.48) LMNAMAPK1SMN1; SMN2TDP1ALDH1A1
SCHEMBL3917077 0.77 PKM (0.38) MAPK1TDP1ALDH1A1KDM4EHTT
SCHEMBL1804135 0.74 RIPK1 (0.46) LMNAMAPK1ALDH1A1KDM4EHTT
SCHEMBL5156459 0.69 ALDH1A1 (0.48) LMNASMN1; SMN2ALDH1A1KDM4EHTT
SCHEMBL1804255 0.69 HTT (0.46) LMNASMN1; SMN2TDP1ALDH1A1GAA
SCHEMBL3918461 0.69 MEN1 (0.61) SMN1; SMN2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US claimed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP claimed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
EP-1730144-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5|DECAN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2006-12-13 EP claimed
WO-2005095398-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2005-10-13 WO claimed
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US disclosed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP disclosed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed
EP-1730144-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5|DECAN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2006-12-13 EP disclosed
WO-2005095398-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ONE COMPOUNDS Grünenthal GmbH (DE) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds THPO, UGT1A8, UGT1A4 LMNA 1640/4885MAPK1 3196/4885SMN1; SMN2 1274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.